Liquidia (LQDA) Accion Foro

$UTHR (-0,66 %) time is running out and I'm getting downright panicky. Not even a month left until $LQDA (+1,86 %) the sale of the PAH drug starts (PH-ILD approval still pending). Liquidia CEO (former CEO of UTHR) aims to gain 80-90% of market share.

TaxesAreTheft

@TaxesAreTheft

9Lun·

My opinion on $LQDA (+1,86 %)

Anyone interested in BioTech shares should definitely take a look here.

Disclaimer: I am well aware of the moral reprehensibility of investing in drugs that are essential for patients' survival. PAH is incurable.

The company recently won the patent case against $UTHR (-0,66 %) won. Now there is a counterclaim. The drug in question is already approved by the FDA for the treatment of PAH, now only the additional approval for PH-ILD is pending. The market for both is worth billions and their drug is superior to UTHR (especially in ease of administration and efficacy), so it is expected to gain a relatively large share of this rapidly growing market (7.3 billion). PAH and PH-ILD drugs are real cash cows, growth forecast is >5% per year.

Personal price target is 60-70$ per share if they gain at least 5% market share (approx. 300-400 million in revenue)

with more optimistic developments you can imagine how sales can develop.

There is also the possibility that the company will be bought out.

For me personally, risk and reward are absolutely acceptable here.

PAH market: https://www.precedenceresearch.com/pulmonary-arterial-hypertension-market/amp

The drug:

https://liquidia.com/static-files/83cf40bb-70ba-4345-90ed-307e89e0bafb

www.precedenceresearch.comSearch Reports - Precedence Research

3

TaxesAreTheft

@TaxesAreTheft

9Lun·

My opinion on $LQDA (+1,86 %)

Anyone interested in BioTech shares should definitely take a look here.

Disclaimer: I am well aware of the moral reprehensibility of investing in drugs that are essential for patients' survival. PAH is incurable.

The company recently won the patent case against $UTHR (-0,66 %) won. Now there is a counterclaim. The drug in question is already approved by the FDA for the treatment of PAH, now only the additional approval for PH-ILD is pending. The market for both is worth billions and their drug is superior to UTHR (especially in ease of administration and efficacy), so it is expected to gain a relatively large share of this rapidly growing market (7.3 billion). PAH and PH-ILD drugs are real cash cows, growth forecast is >5% per year.

Personal price target is 60-70$ per share if they gain at least 5% market share (approx. 300-400 million in revenue)

with more optimistic developments you can imagine how sales can develop.

There is also the possibility that the company will be bought out.

For me personally, risk and reward are absolutely acceptable here.

PAH market: https://www.precedenceresearch.com/pulmonary-arterial-hypertension-market/amp

The drug:

https://liquidia.com/static-files/83cf40bb-70ba-4345-90ed-307e89e0bafb

www.precedenceresearch.comSearch Reports - Precedence Research

2

1 Comentario